Biocon Biologics to buy biosimilars business of Viatris for up to $3.3bn
Biocon Biologics Limited (BBL), a subsidiary of Indian biopharma company Biocon, has agreed to acquire the biosimilars business of Viatris, a US-based pharma company, in a deal worth up to $3.33 billion in a move to create a fully integrated global biosimilars enterprise. The consideration includes cash of up to $2.33 billion and $1 billion […]